Loading...
•
Sep 30, 2022
Janux Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022 and provided a business update.
Key Takeaways
Janux Therapeutics reported a net loss of $16.7 million for the third quarter of 2022, with cash and cash equivalents and short-term investments totaling $338.8 million. The company dosed the first patient with JANX007 in a Phase 1 clinical trial and anticipates submitting an IND for EGFR-TRACTr (JANX008) in the second half of 2022.
First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients.
Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023.
IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted in 2H 2022.
Cash and cash equivalents and short-term investments totaled $338.8 million at the end of the third quarter 2022.